- Name: Shulin Chen
- Title: Associate Chief Technician
- Email: chenshl@sysucc.org.cn
- Phone:
Profile
He has over 10 years of professional experience specializing in clinical immunological testing. The main research focuses on precision medicine in oncology, including cancer immunity and immunotherapy, liquid biopsies, non-invasive progression monitoring, individualized treatment effect assessment, treatment outcome prediction, and individual consultation.
Interests
Serum biomarkers for early tumor screening, treatment effect assessment, and treatment outcome prediction.
Education
Bachelor of Medicine, Third Military Medical University
Master of Medicine, Sun Yat-sen University
Doctor of Biology and Medicine, Sun Yat-sen University
Master of Medicine, Sun Yat-sen University
Doctor of Biology and Medicine, Sun Yat-sen University
Publications
1. Zang T, Luo X, Mo Y, Lin J, Lu W, Li Z, Zhou Y, Chen S. A novel model for predicting immunotherapy response and prognosis in NSCLC patients. Cancer Cell Int. 2025 May 15;25(1):178. doi: 10.1186/s12935-025-03800-3. PMID: 40375214; PMCID: PMC12083170.
2. Wu M, Zou F, He S, Pi Y, Song Y, Chen S, Li L. Serum Osteopontin Enhances Hepatocellular Carcinoma Diagnosis and Predicts Anti-PD-L1 Immunotherapy Benefit. J Hepatocell Carcinoma. 2025 Apr 13;12:729-745. doi: 10.2147/JHC.S514144. PMID: 40255899; PMCID: PMC12007010.
3. Wu YX, Tian BY, Ou XY, Wu M, Huang Q, Han RK, He X, Chen S. A novel model for predicting prognosis and response to immunotherapy in nasopharyngeal carcinoma patients. Cancer Immunol Immunother. 2024 Jan 18;73(1):14. doi: 10.1007/s00262-023-03626-w. PMID: 38236288; PMCID: PMC10796600.